Morgan Stanley Maintains Equal-Weight on Nurix Therapeutics, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn has maintained an Equal-Weight rating on Nurix Therapeutics (NASDAQ:NRIX) and raised the price target from $11 to $12.
July 17, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Nurix Therapeutics and raised the price target from $11 to $12.
The news is directly related to Nurix Therapeutics and is likely to have a positive impact on its stock price in the short term. The increase in price target by a reputable financial institution like Morgan Stanley indicates a positive outlook for the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100